11 April 2023
Deltex Medical Group plc
("Deltex Medical", the "Company" or the "Group")
Issue of equity to satisfy certain outstanding equity-settled non-executive directors' fees
The Board of Deltex Medical (AIM: DEMG), the global leader in oesophageal doppler monitoring, announces the issue of 9,993,805 new ordinary shares of 1p each in the capital of the Company ("Ordinary Shares"), at an issue price of 1.1 pence per new Ordinary Share (the "Issue Price"). The Issue Price represents the Company's closing mid-market price on 6 April 2023.
The new Ordinary Shares are being issued in order to satisfy certain deferred non-executive directors' fees for the year ended 31 December 2021 ("Fee Shares"). In previous years, the Company has settled the deferred non-executive directors' fees of a calendar year in July of the following year. This was last done on 16 July 2021 in respect of the fees ended 31 December 2020. The fees for the year ended 31 December 2021 were expected to be settled on or around July 2022. However, the Company was in and has continued to be in a closed period since that time. Following the publication of the results for the year ended 31 December 2022, the Company is now in a position to settle such outstanding non-executive directors' fees.
Further details of the new Ordinary Shares to be issued to each of the Deltex Medical directors are set out in the table below.
| | | | Resultant holding post Fee Shares | |
| Director | Current Ordinary Shares held | Fee Shares issued | Ordinary Shares Held | As a percentage of the enlarged share capital |
| Nigel Keen | 99,852,821 | 3,448,351 | 103,301,172 | 14.57% |
| Julian Cazalet | 27,153,971 | 2,181,818 | 29,335,789 | 4.14% |
| Mark Wippell | 11,037,875 | 2,181,818 | 13,219,693 | 1.86% |
| Chris Jones | 4,297,291 | 2,181,818 | 6,479,109 | 0.91% |
Application for admission to trading and total voting rights
Application has been made for 9,993,805 new Ordinary Shares to be admitted to trading on AIM, which is expected to take effect on or around 17 April 2023 ("Admission").
Following Admission, the Company's issued share capital will comprise 709,057,601 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
For further information, please contact:
| Deltex Medical Group plc | 01243 774 837 |
| Nigel Keen, Chairman | investorinfo@Deltexmedical.com |
| Andy Mears, Chief Executive | |
| Natalie Wettler, Group Finance Director | |
| | |
| Nominated Adviser and Broker | 020 3328 5656
|
| Jeremy Porter / Vivek Bhardwaj (Corporate Finance) | info@allenbycapital.com |
| Tony Quirke / Stefano Aquilino (Sales & Corporate Broking) | |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
| 1. | Details of the person discharging managerial responsibilities / person closely associated | ||||||||||||||||
| a) | Name | PDMRs:
| |||||||||||||||
| 2. | Reason for the Notification | ||||||||||||||||
| a) | Position/status | See 1a) above | |||||||||||||||
| b) | Initial notification/Amendment | Initial Notification | |||||||||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||||||||
| a) | Name | Deltex Medical Group Plc | |||||||||||||||
| b) | LEI | 213800XN34P6LI8J6M39 | |||||||||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||||||||
| a) | Description of the Financial instrument, type of instrument | Ordinary shares of 0.1p each in Deltex Medical Group Plc
| |||||||||||||||
| Identification code | ISIN: GB0059337583 | ||||||||||||||||
| b) | Nature of the transaction | Fee shares | |||||||||||||||
| c) | Price(s) and volume(s) |
| |||||||||||||||
| d) | Aggregated information: | | |||||||||||||||
| | - Aggregated volume | 9,993,805 | |||||||||||||||
| | - Price | 1.1p | |||||||||||||||
| e) | Date of the transaction | 11 April 2023 | |||||||||||||||
| f) | Place of the transaction | Outside a trading venue | |||||||||||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.